Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Expert Opinion on Therapeutic Targets|April 2, 2003
MAPKs: new targets for neurodegenerationSarah J Harper, Neil WilkieDrug News & Perspectives|April 5, 2003
Trk Neurotrophin Receptor ActivatorsScott J. Pollack, Sarah J. HarperNeuroreport|June 13, 2003
CEP-1347 promotes survival of NGF responsive neurones in primary DRG explantsJames G Bilsland, Sarah J HarperCurrent Drug Targets. CNS and Neurological Disorders|May 29, 2003
Small molecule Trk receptor agonists and other neurotrophic factor mimeticsScott J Pollack, Sarah J HarperArchives of Biochemistry and Biophysics|May 24, 2005
Substituting c-Jun N-terminal kinase-3 (JNK3) ATP-binding site amino acid residues with their p38 counterparts affects binding of JNK- and p38-selective inhibitorsMichael Fricker, Philip Lograsso, Semantha Ellis, et al.The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|March 30, 2002
Caspase inhibitors attenuate 1-methyl-4-phenylpyridinium toxicity in primary cultures of mesencephalic dopaminergic neuronsJames Bilsland, Sophie Roy, Steve Xanthoudakis, et al.The Journal of Pharmacology and Experimental Therapeutics|November 14, 2006
The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouseJonathan D Best, David W Smith, Michael A Reilly, et al.Ambio|September 26, 2025
Designing gender-inclusive data systems in small-scale fisheriesSarah J Harper, Meryl Williams, Danika Kleiber, et al.Pageof 1